BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11762814)

  • 1. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
    Pectasides D; Aravantinos G; Kalofonos H; Kiamouris C; Bafaloukos D; Xiros N; Nicolaides C; Visvikis A; Dimopoulos MA
    Ann Oncol; 2001 Oct; 12(10):1417-22. PubMed ID: 11762814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
    Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y
    Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
    Stathopoulos GP; Rigatos SK; Dimopoulos MA; Giannakakis T; Foutzilas G; Kouroussis C; Janninis D; Aravantinos G; Androulakis N; Agelaki S; Stathopoulos JG; Georgoulias V;
    Ann Oncol; 2003 Mar; 14(3):388-94. PubMed ID: 12598343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Boukovinas I; Androulakis N; Kentepozidis N; Polyzos A; Papakotoulas P; Ziras N; Kotsakis A; Vardakis N; Karampeazis A; Markos V; Kostakopoulos A; Constantinides CA; Samonis G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):351-6. PubMed ID: 21748359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
    J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
    Pagliaro LC; Millikan RE; Tu SM; Williams D; Daliani D; Papandreou CN; Logothetis CJ
    J Clin Oncol; 2002 Jul; 20(13):2965-70. PubMed ID: 12089226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
    Chen YM; Perng RP; Whang-Peng J; Wu HW; Lin WC; Tsai CM
    Lung Cancer; 2000 Dec; 30(3):199-202. PubMed ID: 11137205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
    Lin CC; Hsu CH; Huang CY; Keng HY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Anticancer Drugs; 2007 Apr; 18(4):487-91. PubMed ID: 17351402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
    Boukovinas I; Androulakis N; Vamvakas L; Papakotoulas P; Ziras N; Polyzos A; Kalykaki A; Kotsakis A; Xenidis N; Gioulmbasanis I; Mavroudis D; Georgoulias V
    Ann Oncol; 2006 Nov; 17(11):1687-92. PubMed ID: 16968872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
    Hu S; He X; Dong M; Jia B; Zhou S; Yang J; Yang S; Zhang C; Liu P; Qin Y; Gui L
    Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):632-6. PubMed ID: 26714607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
    Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
    Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
    Balar AV; Apolo AB; Ostrovnaya I; Mironov S; Iasonos A; Trout A; Regazzi AM; Garcia-Grossman IR; Gallagher DJ; Milowsky MI; Bajorin DF
    J Clin Oncol; 2013 Feb; 31(6):724-30. PubMed ID: 23341513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
    Polyzos A; Tsavaris N; Gogas H; Lagadas A; Polyzos K; Giannakopoulos K; Felekouras E; Tsigris C; Karatzas T; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2009 Jul; 29(7):2681-6. PubMed ID: 19596946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.
    Pectasides D; Mylonakis N; Farmakis D; Nikolaou M; Koumpou M; Katselis I; Gaglia A; Kostopoulou V; Karabelis A; Kosmas C
    Anticancer Res; 2003; 23(5b):4205-11. PubMed ID: 14666626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
    Takahashi S; Suzuki M; Kume H; Matsumoto S; Okamoto N; Nishimatsu H; Tomita K; Kitamura T
    Jpn J Clin Oncol; 2005 Feb; 35(2):79-83. PubMed ID: 15709091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
    Piantedosi FV; Caputo F; Mazzarella G; Gilli M; Pontillo A; D'Agostino D; Campbell S; Marsico SA; Bianco A
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):803-7. PubMed ID: 17639396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
    Bamias A; Moulopoulos LA; Koutras A; Aravantinos G; Fountzilas G; Pectasides D; Kastritis E; Gika D; Skarlos D; Linardou H; Kalofonos HP; Dimopoulos MA
    Cancer; 2006 Jan; 106(2):297-303. PubMed ID: 16342065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.